Synthesis and biological evaluation of PET tracers designed for imaging of calcium activated potassium channel 3.1 (KCa3.1) channels in vivo-Reference-Cited by-同舟云学术

Synthesis and biological evaluation of PET tracers designed for imaging of calcium activated potassium channel 3.1 (KCa3.1) channels in vivo

Published:2021 Issue:48 Volume:11 Page:30295-30304
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Brömmel Kathrin¹,Konken Christian Paul²^ORCID,Börgel Frederik¹,Obeng-Darko Henry¹,Schelhaas Sonja³,Bulk Etmar⁴,Budde Thomas⁵⁶,Schwab Albrecht⁴⁶,Schäfers Michael²³⁶,Wünsch Bernhard¹⁶^ORCID

Affiliation:

1. Institute for Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University Münster, Corrensstraße 48, D-48149 Münster, Germany

2. Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, D-48149 Münster, Germany

3. European Institute for Molecular Imaging (EIMI), Westphalian Wilhelms-University Münster, Waldeyerstraße 15, D-48149 Münster, Germany

4. Institute for Physiology II, University Hospital Münster, Robert-Koch-Straße 27b, D-48149 Münster, Germany

5. Institute for Physiology I, University Hospital Münster, Robert-Koch-Straße 27a, D-48149 Münster, Germany

6. Cells-in-Motion Interfaculty Center, Westphalian Wilhelms-University Münster, Waldeyerstraße 15, D-84149 Münster, Germany

Abstract

Expression of the Ca2+ activated potassium channel 3.1 (KCa3.1) channel (also known as the Gàrdos channel) is dysregulated in many tumor entities and has predictive power with respect to patient survival.

Funder

Deutsche Forschungsgemeinschaft

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/RA/D1RA03850H

Reference46 articles.

1. Targeted Inhibition of KCa3.1 Channel Attenuates Airway Inflammation and Remodeling in Allergic Asthma

2. The K+channels KCa3.1 and Kv1.3 as novel targets for asthma therapy

3. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia

4. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

5. Dose-Escalation Study of ICA-17043 in Patients with Sickle Cell Disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging of K _Ca 3.1 Channels in Tumor Cells with PET and Small‐Molecule Fluorescent Probes;ChemMedChem;2022-11-22

2. Imaging of the calcium activated potassium channel 3.1 (K _Ca 3.1) in vivo using a senicapoc‐derived positron emission tomography tracer;Archiv der Pharmazie;2022-09-25